Home Cart Sign in  
Chemical Structure| 1000413-72-8 Chemical Structure| 1000413-72-8

Structure of Fasiglifam
CAS No.: 1000413-72-8

Chemical Structure| 1000413-72-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Fasiglifam (TAK-875) is a potent, selective, and orally bioavailable GPR40 agonist with an EC50 of 72 nM.

Synonyms: Tak-875

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Fasiglifam

CAS No. :1000413-72-8
Formula : C29H32O7S
M.W : 524.63
SMILES Code : O=C(O)C[C@@H]1COC2=CC(OCC3=CC(C4=C(C)C=C(OCCCS(=O)(C)=O)C=C4C)=CC=C3)=CC=C12
Synonyms :
Tak-875
MDL No. :MFCD18251445
InChI Key :BZCALJIHZVNMGJ-HSZRJFAPSA-N
Pubchem ID :24857286

Safety of Fasiglifam

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Fasiglifam

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293 cells 10 µM 2 hours Evaluate the binding ability of Fasiglifam to GPR40 receptor PMC5917010
CHO-GPR40 cells 5 μM 1 hour To determine agonistic activity of compounds against FFA1 receptor, results showed compounds 4b and 4c activated 80% and 61% receptor activity at 5 μM concentration, respectively PMC6021034
Mouse colonic mucosal cells 300 nM 10–15 minutes To compare the pharmacology of FFA1 and FFA4 agonists, finding selective agonists more potent than GW9508 PMC5715575
Human airway smooth muscle (HASM) cells 10 µM 30 min TAK875 significantly attenuated histamine-induced MLC phosphorylation and cortical tension development, while GW9508 showed little effect. PMC7708129
RIN-m5f cells 30 or 150 mg/mL 48 hours To evaluate the effect of YD on insulin secretion in high-glucose and high-fat injured RIN-m5f cells. Results showed that high concentration YD (150 mg/mL) significantly increased glucose-stimulated insulin secretion (GSIS) levels, similar to the TAK-875 group. PMC10043368
Human liver organoids (HLOs) 3, 10, 30 μM 7 days To evaluate oxidative stress and immune responses induced by TAK-875. Results showed that TAK-875 treatment led to increased ROS formation and significant release of inflammatory cytokines MCP-1 and IL-6. PMC9981852

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice GPR40 knockout mice Oral 10 mg/kg Single dose Evaluate the effect of Fasiglifam on blood glucose and insulin levels PMC5917010
SD rats Oral glucose tolerance test Oral 10 mg/kg Single dose Evaluate the effect of HWL-088 on glucose tolerance in rats PMC7174891
ZDF (fa/fa) rats Type 2 diabetic rat model Gavage 10 mg/kg/day Once daily for 10 weeks To evaluate the effect of TAK-875 on blood glucose and insulin secretion in type 2 diabetic rats. Results showed that TAK-875 significantly reduced fasting blood glucose (FBG) and the area under the curve (AUC) of OGTT, and increased the AUC of insulin release test (IRT) and glucose-stimulated insulin secretion (GSIS). PMC10043368
Mice Diabetes model Intraperitoneal injection 27 mg/kg Single dose To evaluate the effect of FFA1 agonist on blood glucose control, finding it improved glucose tolerance PMC5715575
Mice Gpr40 knockout and wild-type mice Oral 30 mg/kg Single dose, evaluated after 30 minutes To assess the effect of GPR40 agonists on plasma GLP-1 and GIP levels. Results showed that Gq+Gs agonists like AM-1638 and AM-5262 significantly increased plasma GLP-1 and GIP levels. PMC4314522
Rats Type 1 diabetes model rats Oral 5 and 10 mg/kg Immediately before glucose load TAK-875 (a GPR40 agonist) did not decrease postprandial blood glucose levels up to 30 min after glucose load. PMC10424117
Collaborative Cross mice Collaborative Cross mice Oral gavage 600 mg/kg Single dose To evaluate the mechanisms of TAK-875-induced liver injury and genetic risk factors in Collaborative Cross mice. Results showed that a single high dose of TAK-875 did not cause overt liver injury, but gene expression profiling revealed transcriptional changes associated with immune response, bile acid homeostasis, oxidative stress, and mitochondrial dysfunction. PMC8936092

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01433393 Diabetes Mellitus Phase 3 Completed - Japan ... More >> Kisarazu-shi, Chiba, Japan Matsuyama-shi, Ehime, Japan Fukuoka-shi Nishi-ku, Fukuoka, Japan Kasuga-shi, Fukuoka, Japan Naka-shi, Ibaragi, Japan Tsuchiura-shi, Ibaragi, Japan Takamatsu-shi, Kagawa, Japan Kyoto-shi Fushimi-ku, Kyoto, Japan Nagasaki-shi, Nagasaki, Japan Kashihara-shi, Nara, Japan Kashiwara-shi, Osaka, Japan Osaka-shi Tsurumi-ku, Osaka, Japan Sakai-shi Nishi-ku, Osaka, Japan Shimotsuke-shi, Tochigi, Japan Chiyoda-ku, Tokyo, Japan Itabashi-ku, Tokyo, Japan Ota-ku, Tokyo, Japan Shinjuku-ku, Tokyo, Japan Toshima-ku, Tokyo, Japan Less <<
NCT01585792 Diabetic Patients Phase 3 Completed - Japan ... More >> Fukuoka-shi, Fukuoka, Japan Sumida-ku, Tokyo, Japan Less <<
NCT01007097 Diabetes Mellitus, Type 2 Phase 2 Completed - -
NCT01433406 Diabetes Mellitus Phase 3 Completed - -
NCT01414920 Diabetes Mellitus, Type 2 Phase 2 Completed - -
NCT01433419 Diabetes Mellitus Phase 3 Completed - Japan ... More >> Katori-shi, Chiba, Japan Niihama-shi, Ehime, Japan Chikushino-shi, Fukuoka, Japan Fukuoka-shi, Fukuoka, Japan Onga-gun, Fukuoka, Japan Yukuhashi-shi, Fukuoka, Japan Hiroshima-shi, Hiroshima, Japan Chitose-shi, Hokkaido, Japan Sapporo-shi, Hokkaido, Japan Koga-shi, Ibaragi, Japan Ushiku-shi, Ibaragi, Japan Chigasaki-shi, Kanagawa, Japan Kamakura-shi, Kanagawa, Japan Minamata-shi, Kumamoto, Japan Yatsushiro-shi, Kumamoto, Japan Sasebo-shi, Nagasaki, Japan Kashihara-shi, Nara, Japan Okinawa-shi, Okinawa, Japan Izumi-shi, Osaka, Japan Suita-shi, Osaka, Japan Fujimi-shi, Saitama, Japan Shimotsuga-gun, Tochigi, Japan Komatsushima-shi, Tokushima, Japan Bunkyo-ku, Tokyo, Japan Chiyoda-ku, Tokyo, Japan Mitaka-shi, Tokyo, Japan Shibuya-ku, Tokyo, Japan Shinjuku-ku, Tokyo, Japan Toshima-ku, Tokyo, Japan Shunan-shi, Yamaguchi, Japan Ube-shi, Yamaguchi, Japan Less <<
NCT01456195 Diabetes Mellitus, Type 2 Phase 3 Completed - -
NCT01549964 Glycemic Control Phase 3 Terminated(Due to concerns abo... More >>ut potential liver safety (See Detailed Description)) Less << - -
NCT01834274 Diabetes Mellitus, Type 2 Phase 3 Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << - -
NCT01834274 - Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << - -
NCT01982253 Type 2 Diabetes Mellitus Phase 2 Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << - -
NCT01982253 - Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << - -
NCT01481116 - Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << - -
NCT01549964 - Terminated(Due to concerns abo... More >>ut potential liver safety (See Detailed Description)) Less << - -
NCT02015780 Type 2 Diabetes Mellitus ... More >> Chronic Kidney Disease Less << Phase 3 Withdrawn(Due to potential con... More >>cerns about liver safety (See Detailed Description)) Less << January 2016 -
NCT01481116 Diabetes Mellitus, Type 2 Phase 3 Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << - -
NCT01456195 - Completed - -
NCT01829464 Diabetes Phase 3 Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << - -
NCT01829477 Diabetes Mellitus, Type 2 Phase 3 Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << - -
NCT00949091 Diabetes Mellitus, Type 2 Phase 1 Completed - -
NCT01496443 Pharmacokinetics Phase 1 Completed - United States, Texas ... More >> San Antonio, Texas, United States Less <<
NCT01829477 - Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << - -
NCT01647542 Type 2 Diabetes Mellitus Phase 3 Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << - -
NCT01647542 - Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << - -
NCT01609582 - Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << - -
NCT01829464 - Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << - -
NCT01609582 Type 2 Diabetes ... More >> Cardiovascular Disease Less << Phase 3 Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.91mL

0.38mL

0.19mL

9.53mL

1.91mL

0.95mL

19.06mL

3.81mL

1.91mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories